Vanguard Fiduciary Trust
BNTC icon

Vanguard Fiduciary Trust’s Benitec Biopharma BNTC Stock Holding History

Vanguard Fiduciary Trust’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.15M Sell
160,995
-10,758
-6% -$128K ﹤0.01% 2629
2026
Q1 		$1.83M Buy
+171,753
New +$1.99M ﹤0.01% 2613

Other funds holding BNTC

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

Vanguard Fiduciary Trust's BNTC Position: Q2 2026 in Review

Vanguard Fiduciary Trust reduced its Benitec Biopharma (BNTC) stake by 6.3% in Q2 2026, selling an estimated $128K and leaving 160,995 shares worth $2.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2629.

Vanguard Fiduciary Trust first reported a position in BNTC in Q1 2026 and has held it in 2 quarters since. 87 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

  • Vanguard Fiduciary Trust held 160,995 shares of Benitec Biopharma worth $2.15M as of Q2 2026.
  • Vanguard Fiduciary Trust sold 10,758 Benitec Biopharma shares in Q2 2026, an estimated $128K.
  • Benitec Biopharma made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2629 holding.
  • Vanguard Fiduciary Trust first reported a position in Benitec Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 87 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.